Active Ingredient History
Resminostat is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Hepatocellular (Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Glomerulonephritis, IGA (Phase 4)
Hodgkin Disease (Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Mycosis Fungoides (Phase 2)
Neoplasms ()
Sezary Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue